Press-release for stocks related to disease for ppruf

| -21.79% | O: -0.59% H: 0.27% C: -1.83%
PPRUY | News | $36.03 -0.11% 330K

| -21.79% | O: -1.85% H: 0.2% C: -0.07%
PCVX | $60.65 -2.85% -2.93% 660K

| -12.94% | O: 0.2% H: 0.18% C: -0.42%
STRO M | $3.76 -1.05% -1.06% 770K

| -23.23% | O: 0.2% H: 1.81% C: -3.43%
vax-24 disease pneumococcal study

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K

| -12.79% | O: 0.92% H: 0.76% C: -1.38%
PPRUY | News | $36.03 -0.11% 330K

| -13.45% | O: -0.55% H: 1.4% C: 1.28%
PCVX | $60.65 -2.85% -2.93% 660K

| -2.92% | O: 0.26% H: 6.59% C: 6.23%
STRO M | $3.76 -1.05% -1.06% 770K

| -19.15% | O: -0.43% H: 6.84% C: 6.62%
vax-31 disease pneumococcal study

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K

| -16.85% | O: -1.41% H: 1.77% C: -1.32%
PPRUY | News | $36.03 -0.11% 330K

| -16.35% | O: 1.28% H: 0.21% C: -1.4%
PCVX | $60.65 -2.85% -2.93% 660K

| 23.38% | O: 0.59% H: 0.63% C: -5.62%
STRO M | $3.76 -1.05% -1.06% 770K

| 56.38% | O: 4.12% H: 0.0% C: -11.07%
vax-31 disease pneumococcal study

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-10-19 (Crawled : 12:30) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K

| -17.42% | O: -0.57% H: 1.09% C: 0.98%
PPRUY | News | $36.03 -0.11% 330K

| -15.86% | O: 1.4% H: 0.53% C: -0.81%
PCVX | $60.65 -2.85% -2.93% 660K

| 35.63% | O: 0.24% H: 2.54% C: 0.78%
STRO M | $3.76 -1.05% -1.06% 770K

| 7.95% | O: -0.28% H: 0.0% C: -6.27%
vax-31 fda drug disease pneumococcal clearance application

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K

| -31.45% | O: 3.26% H: 0.0% C: -0.57%
PPRUY | News | $36.03 -0.11% 330K

| -32.03% | O: 1.02% H: 0.9% C: 0.75%
PCVX | $60.65 -2.85% -2.93% 660K

| 31.13% | O: -2.77% H: 2.2% C: 0.65%
STRO M | $3.76 -1.05% -1.06% 770K

| -20.0% | O: -1.47% H: 1.71% C: 0.64%
vax-24 disease pneumococcal ongoing study

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -42.24% | O: 2.52% H: 2.74% C: 2.74%
PPRUY | News | $36.03 -0.11% 330K

| -43.2% | O: 1.88% H: 1.04% C: 0.57%
PCVX | $60.65 -2.85% -2.93% 660K

| 69.42% | O: -0.52% H: 0.55% C: -1.06%
STRO M | $3.76 -1.05% -1.06% 770K

| -20.34% | O: -1.05% H: 2.86% C: -5.08%
vax-24 disease pneumococcal study phase 2

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -43.3% | O: -3.64% H: 3.09% C: 1.33%
PPRUY | News | $36.03 -0.11% 330K

| -43.19% | O: -1.68% H: 1.12% C: -0.58%
PCVX | $60.65 -2.85% -2.93% 660K

| 41.18% | O: -0.93% H: 1.96% C: 0.55%
STRO M | $3.76 -1.05% -1.06% 770K

| -38.91% | O: -1.13% H: 5.37% C: -0.98%
vax-24 fda clearance drug disease application pneumococcal

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -32.19% | O: 1.3% H: 2.07% C: 1.45%
PPRUY | News | $36.03 -0.11% 330K

| -33.54% | O: 0.44% H: 0.55% C: -0.17%
PCVX | $60.65 -2.85% -2.93% 660K

| 33.23% | O: -0.13% H: 0.45% C: -1.58%
STRO M | $3.76 -1.05% -1.06% 770K

| -53.09% | O: -0.86% H: 7.35% C: 5.23%
vax-24 fda designation disease granted therapy pneumococcal

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published: 2022-10-24 (Crawled : 11:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -18.53% | O: 0.55% H: 3.41% C: -0.9%
PPRUY | News | $36.03 -0.11% 330K

| -20.27% | O: -0.01% H: 0.83% C: -0.01%
PCVX | $60.65 -2.85% -2.93% 660K

| 203.35% | O: 70.8% H: 2.7% C: -6.12%
STRO M | $3.76 -1.05% -1.06% 770K

| -32.62% | O: 0.71% H: 14.96% C: 13.91%
candidate disease topline vaccine positive study pneumococcal

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K

| -51.09% | O: -8.77% H: 6.66% C: 5.47%
PPRUY | News | $36.03 -0.11% 330K

| -50.27% | O: -5.49% H: 3.87% C: 3.65%
PCVX | $60.65 -2.85% -2.93% 660K

| 208.45% | O: -8.4% H: 22.28% C: 21.9%
STRO M | $3.76 -1.05% -1.06% 770K

| -53.94% | O: -1.09% H: 8.21% C: 8.09%
vax-24 disease phase 1 pneumococcal

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -55.66% | O: 2.64% H: 0.0% C: -0.39%
PPRUY | News | $36.03 -0.11% 330K

| -56.36% | O: -0.99% H: 0.0% C: -1.16%
PCVX | $60.65 -2.85% -2.93% 660K

| 161.1% | O: 4.14% H: 2.57% C: -1.0%
STRO M | $3.76 -1.05% -1.06% 770K